Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Korean J Intern Med
Hauptverfasser: Ock, Chan-Young, Yoo, Shin-Hye, Keam, Bhumsuk, Kim, Miso, Kim, Tae Min, Jeon, Yoon Kyung, Kim, Dong-Wan, Chung, Doo Hyun, Heo, Dae Seog
Format: Artigo
Sprache:Inglês
Veröffentlicht: The Korean Association of Internal Medicine 2019
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718771/
https://ncbi.nlm.nih.gov/pubmed/29950554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2018.011
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge